Ministry of science and technology name clinical effective two anti epidemic drugs hanging net price exposure! RMB 780 / box

On February 15, at a press conference held by the joint defense and control mechanism of the State Council, Zhang Xinmin, director of the biological center of the Ministry of science and technology, said that on the basis of multiple rounds of screening, the scientific research team focused on a few drugs, including chloroquine phosphate, rendisivir, and fabiravir As chloroquine phosphate and fabinavir are two drugs that have been listed, and randicivir is still in the clinical research and development stage, and is still in the clinical trial stage, the first two listed drugs were quickly linked to the Internet, and at the same time, the drug price was also exposed Novel coronavirus: the clinical effective February 15th joint press and prevention joint control mechanism introduced the news conference, saying that since the outbreak of the outbreak, our scientific research personnel have been awake all night and tackled the new coronavirus urgently A total of 70000 drugs were screened nationwide, 5000 potentially effective products were selected, and 100 of them were selected for in vitro test, and finally focused on three drugs According to Zhang Xinmin, chloroquine phosphate is an antimalarial drug that has been on the market for many years In vitro experiments show that chloroquine phosphate has a good inhibitory effect on the new coronavirus The novel coronavirus pneumonia is a preliminary result of clinical results Fabiravir is an overseas listed drug for the treatment of influenza At present, clinical trials have been carried out in Shenzhen, with 70 patients in the group, including the control group, initially showing obvious efficacy and low adverse reactions On the 3rd to 4th day after treatment, the negative rate of viral nucleic acid in the treatment group was significantly higher than that in the control group Randicivir, also known as ridcivir in media reports, is currently promoting clinical research in more than 10 medical institutions in Wuhan 168 patients have been enrolled in the group of severe patients, 17 patients have been enrolled in the group of light and common patients, and we are looking forward to the results of clinical trials as soon as possible Two waves of policy dividends enjoyed by the pharmaceutical industry two days after the press conference of the Ministry of science and technology On February 17, Haizheng pharmaceutical released a notice saying that faveravir (also known as fapinavir) obtained both the drug registration approval and the drug clinical trial approval At the same time of approval, Haizheng pharmaceutical's favilavir has also been online Shandong, Beijing, Shanghai, Heilongjiang, Jiangxi and other companies have issued announcements to directly online favilavir Among them, Shandong announced the price of the drug at the same time of online listing, the announcement shows that the price of Haizheng pharmaceutical's faveravir is 780 yuan for 0.2g40 tablets / box, 398 yuan for 0.2g20 tablets / box, and the price of each tablet is close to 20 yuan On February 20, Shandong released the information of the fourth batch of anti epidemic drugs on the Internet According to the announcement, the specification of chloroquine phosphate of Guangdong Zhongsheng Pharmaceutical Co., Ltd is 0.25g, the price of 40 tablets / bottle is 88.00 yuan; the specification of Sichuan Shenghe Pharmaceutical Co., Ltd is 0.25g, the price of 90 Tablets / box is 234.78 yuan; the specification of Shanghai Xinyi balance Pharmaceutical Co., Ltd is 0.25g, the price of 100 tablets / bottle is 179 yuan, the average price is 2.2 yuan, 2.6 yuan and 1.79 yuan respectively (photo source: Shandong public resources trading center) behind the 10 times price difference: behind the 10 times price difference of exclusive vs multiple production is the market competition Although the patent of favelavir has expired, it is only produced by Haizheng According to the announcement of Haizheng Pharmaceutical Co., Ltd., favilavir tablets were approved to be marketed in Japan in March 2014, which are broad-spectrum antiviral drugs, and the indications are used to treat new or re epidemic influenza in adults (only used when other antiviral drugs are ineffective or ineffective) Fushan Chemical Industry Co., Ltd applied for the first compound patent of fapiravir in August 1999, with a term of 20 years The compound patent expired in August 2019 In June 2016, Haizheng and Toyama Chemical Industry Co., Ltd signed an exclusive license agreement for compound patents Haizheng had not commercialized the drug before After querying IMS database, no sales data of this product in domestic and foreign markets was found In short, it is the exclusive product of Haizheng At present, no other pharmaceutical companies have copied it Chloroquine phosphate, as an old anti malarial drug, has been used in the treatment of malaria since the 1940s and rheumatoid arthritis Its injection and tablet oral regular release dosage forms are included in class a of national medical insurance catalogue (2019 Edition) According to the CPM database of China Pharmaceutical Industry Information Center, at present, there are 35 enterprises of chloroquine phosphate in China, including Shanghai Xinyi balance Pharmaceutical Co., Ltd., Sichuan Shenghe Pharmaceutical Co., Ltd and Chongqing Southwest Pharmaceutical Co., Ltd., among which 4 are APIs, 31 are pharmaceuticals, and Sichuan Shenghe Pharmaceutical Co., Ltd is the main manufacturer However, after the effective information of the drug against the epidemic came out, several pharmaceutical companies have announced the resumption of production and can rapidly supply clinical services 37